These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6614941)

  • 21. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
    Breistøl K; Balzarini J; Sandvold ML; Myhren F; Martinsen M; De Clercq E; Fodstad O
    Cancer Res; 1999 Jun; 59(12):2944-9. PubMed ID: 10383159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recent acquisitions in the metabolism, mechanism of action and toxicity of cytarabine].
    Campio L
    Minerva Med; 1971 Mar; 62(25):1319-32. PubMed ID: 5552474
    [No Abstract]   [Full Text] [Related]  

  • 23. [DCTP (I) combination chemotherapy of adult acute non-lymphocytic leukemia].
    Kobayashi T; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Aiba K; Nagata T; Chinen T; Kuraishi Y; Meguro S; Ichiba K; Abe M
    Rinsho Ketsueki; 1982 Nov; 23(11):1681-8. PubMed ID: 7166808
    [No Abstract]   [Full Text] [Related]  

  • 24. [Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine].
    Tatetsu H; Asou N; Nakamura M; Koh Y; Tajiri T; Matsuno F; Horikawa K; Yonemura Y; Mitsuya H
    Rinsho Ketsueki; 2003 Jul; 44(7):471-3. PubMed ID: 12931567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological properties of ametantrone.
    Ossowska G; Juszkiewicz M; Kleinrok Z
    Ann Univ Mariae Curie Sklodowska Med; 1992; 47():183-93. PubMed ID: 1365795
    [No Abstract]   [Full Text] [Related]  

  • 26. Design of adjuvant chemotherapy based on target cell determinants of drug action: possibilities and limitations.
    Rustum Y; Cheng YC; Pavelic Z; Creaven P; Mihich E
    Recent Results Cancer Res; 1979; 67():126-31. PubMed ID: 377431
    [No Abstract]   [Full Text] [Related]  

  • 27. 3-Triazenopyrroles: synthesis and antineoplastic activity.
    Dattolo G; Cirrincione G; Almerico AM; Aiello E; Grimaudo S; Diana P; Rausa L; Dusonchet L; Crosta L; Tolomeo M
    Farmaco; 1993 Feb; 48(2):191-4. PubMed ID: 8494597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The simultaneous determination of Ara-U and Ara-C, urinary metabolites of N4-behenoyl-1-beta-D-arabinofuranosylcytosine by mass fragmentography (author's transl)].
    Makino Y; Matsubara Y; Watanabe K; Hirobe M
    Yakugaku Zasshi; 1982 Jan; 102(1):49-55. PubMed ID: 7086638
    [No Abstract]   [Full Text] [Related]  

  • 29. [DCTP and DCMP two step therapy in acute non-lymphocytic leukemia (author's transl)].
    Morishima Y; Yamada K; Kawashima K; Ohno R; Ezaki K; Kodera Y; Kobayashi M; Takeyama H; Kato Y; Watanabe E; Suzuki H; Yamaguchi H; Tanimoto M; Minami S; Yokomaku S; Ogura M; Morishita T; Nishiwaki H; Yamada H; Ohara K; Yoshikawa S
    Rinsho Ketsueki; 1980 Jan; 21(1):33-8. PubMed ID: 7373867
    [No Abstract]   [Full Text] [Related]  

  • 30. Sequential studies of daunorubicin and adriamycin in acute nonlymphocytic leukemia.
    Wiernik PH
    Cancer Treat Rep; 1981; 65 Suppl 4():67-71. PubMed ID: 7049382
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of amsacrine and cytarabine on bones in rats].
    Cegieła U; Janiec W
    Przegl Lek; 2000; 57(2):122-6. PubMed ID: 10907356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High remission induction (traditional sino-western HOAP) regimen for acute nonlymphocytic leukemia.
    Chin Med J (Engl); 1980 Aug; 93(8):565-8. PubMed ID: 6772409
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of sialogogic action of cyclocytidine (NSC-145668) and anhydro-ara-5-fluorocytidine (NSC-166641).
    Schneyer CA; Galbraith WM
    Cancer Chemother Rep; 1975; 59(5):1019. PubMed ID: 1203892
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
    Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Special feature of mixed phosphotriester derivatives of cytarabine.
    Gouy MH; Jordheim LP; Lefebvre I; Cros E; Dumontet C; Peyrottes S; Périgaud C
    Bioorg Med Chem; 2009 Sep; 17(17):6340-7. PubMed ID: 19674903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorohydrazines of 4-oxo-4H-1-benzopyran and 1-benzopyran-2,4-dione exhibit antitumor activity against L1210 leukemia.
    Nawrot-Modranka J; Ochocki J; Graczyk J
    Pharmazie; 2004 Sep; 59(9):731-2. PubMed ID: 15497762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Syntheses and antitumor activity of 4-[N'-[N-(2-chloroethyl)-N-nitrosocarbamoyl]hydrazono]-2,2,6,6- tetramethylpiperidine-1-oxyl.
    Gadjeva V; Raikov Z
    Pharmazie; 1999 Mar; 54(3):231-2. PubMed ID: 10192113
    [No Abstract]   [Full Text] [Related]  

  • 38. Quantitative description of morphologic changes effected by antileukemic agents in L1210 leukemia cells.
    Iwasaki H; Liu YP; Nojyo Y; Ueda T; Nakamura T
    Anticancer Res; 1995; 15(1):133-9. PubMed ID: 7733623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYTOSAR-U sterile powder: therapeutic biological effects. Proceedings of a symposium. November 30-December 2, 1986, Kalamazoo, MI.
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):1-275. PubMed ID: 3589683
    [No Abstract]   [Full Text] [Related]  

  • 40. [Specificity of antitumoral substances].
    Le Pecq JB
    Sem Hop; 1980 Feb 18-25; 56(7-8):359-61. PubMed ID: 6154975
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.